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Abstract.  Statin has previously been identified to be a 
57-kD protein present in the nuclei of quiescent and 
senescent human fibroblasts, but not in their replicat- 
ing counterparts (Wang, E.  1985. J.  Cell Biol.  100: 
545-551).  In the present report we demonstrate by 
immunoprecipitation analysis of fractionated cellular 
extracts the existence of two populations of statin.  The 
Triton X-100-soluble statin is found in replicating 
sparse cultures as well as in quiescent confluent cul- 
tures and quiescent serum-starved cultures of young 
human fibroblasts, but the Triton X-100-insoluble,  nu- 
clear envelope-localized statin is present only in the 
quiescent cultures.  Two-dimensional gel analysis of the 
immunoprecipitated cellular fractions reveals that both 
populations of statin have an isoelectric point of 5.3. 
Pulse-chase experiments show that statin is synthe- 
sized as a 57-kD polypeptide and is not processed 
from a precursor of different molecular mass.  Experi- 
ments on serum stimulation of quiescent cells show 
that synthesis of the Triton X-100-insoluble statin 
decreases rapidly during the transition from the GO to 
S phase,  and that this decrease is accompanied by a 
slower reduction in synthesis of the Triton X-100-solu- 
ble statin.  These results suggest that the cellular ex- 
pression of the two populations of statin may be as- 
sociated with the mechanisms controlling the transition 
between the growing state and the quiescent state and 
confirm the previous finding that the Triton X-100-in- 
soluble, nuclear envelope-localized statin could be 
used as a marker for cells arrested at the GO phase of 
the cell cycle. 
S 
TATIN is a  nuclear protein previously identified by a 
mAb (S-30) that is produced by immunizing a mouse 
with the detergent-insoluble extract of senescent hu- 
man fibroblasts (20). Immunofluorescence staining with the 
antibody shows that statin is present in the nuclei of senes- 
cent and quiescent young human fibroblasts but not in the 
nuclei  of replicating young fibroblasts.  Immunoprecipita- 
tions of total cellular extracts with the antibody demonstrate 
that statin is a 57-kD protein present only in nonproliferating 
human fibroblasts. Immunogold labeling localizes the pro- 
tein at the nuclear envelope of  the nonproliferating cells (22). 
However, extensive biochemical characterization of the pro- 
tein has not been carried out. Questions as to whether statin 
is synthesized as a precursor of different molecular mass or 
present  in  cellular  compartments  other  than  the  nuclear 
envelope remain unanswered. 
The nuclear presence of statin is not only characteristic of 
senescent and quiescent young fibroblasts, but also of tissues 
comprised of cells that are at the final stage of differentiation 
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(24).  As  it is  the case for replicating young fibroblasts in 
vitro, statin is noticeably absent in tissues such as epithelium 
of the gastrointestinal tract and kidney whose cells still have 
the potential to divide. While the function of statin is un- 
known, the nuclear expression of the protein has been shown 
to be correlated with the state of cell proliferation. Nuclear 
expression of statin can be induced in young human fibro- 
blasts arrested at the G0/G1 phase of the cell cycle by serum 
starvation or growth-contact inhibition (20, 22, 25). The in- 
duced statin disappears  rapidly from the nuclei when the 
cells are promoted to leave the quiescent state upon serum 
stimulation (25) or removal of growth-contact inhibition by 
subculturing to sparse cell density (22). The nuclear disap- 
pearance of this protein in the cells reentering the S phase 
of the cell cycle precedes initiation of DNA synthesis (25). 
Although a  correlation between the nuclear expression of 
statin and the nonproliferative state of a cell has been demon- 
strated, similar kinds of studies on the total cellular expres- 
sion of the protein have not been done. It will be important 
to know if the nuclear disappearance of statin in cells reenter- 
ing the S phase of the cell cycle is accompanied by a loss in 
the total cellular level of the protein. 
In this paper, we report a biochemical characterization of 
the cellular distribution of statin and of its  synthesis.  The 
relationship between the total cellular expression of the pro- 
tein and the state of cell proliferation is also determined. 
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Cell Cultures 
GM0011, a cell strain of normal human fibroblasts derived from a donor 
of 8  fetal  weeks, was obtained from the Human Genetic Cell Repository 
(Camden,  NJ).  Its in vitro  lifespan, expressed in cumulative population 
doubling level (CPDL), t has previously been determined (20, 21, 23). Cul- 
tures of GM0011 at CPDL less than 15 were used to obtain a fairly homoge- 
neous population of young cells with high replicative capacity. 
All cultures were grown on petri dishes of 10-cm diameter in MEM sup- 
plemented with  10%  FBS and 1% nonessential amino acids at 37°C in a 
humidified atmosphere of 5%  COz as described (20).  Cells were either 
seeded at 7  ×  103 cells/cm  2 and grown to a confluent monolayer (6  ×  105 
cells/cm2), or seeded at 3  ×  103 cells/cm  2 and permitted to grow for 2-3 d 
to obtain a sparse density (8-9  ×  103 celts/cm2). These replicating sparse 
cultures and quiescent confluent cultures were then used for the labeling ex- 
periments described below. 
Preparation of mAb 
The mAb $44-1 was prepared and screened as described (20). This antibody 
was shown by the techniques of immunofluorescence microscopy and im- 
munoprecipitation to react specifically with statin as the mAb S-30 (20) did. 
It has a higher titer than S-30 and therefore was used in the present study. 
Steady-state Metabolic Labeling 
Replicating sparse cultures and quiescent confluent cultures were  rinsed 
with methionine-free MEM three times and labeled with 400 #Ci [35S]me- 
thionine (>1,000 Ci/mmol; New England Nuclear, Boston, MA) in 4 ml of 
methionine-free MEM supplemented with 0.5 or 10%  FBS (for confluent 
and sparse cultures, respectively) and 0.8 ttg/ml of unlabeled L-methionine 
at 3"/°C for  16 h. 
Pulse-Chase Experiments 
Quiescent confluent cultures were rinsed three times with methionine-free 
MEM and pulse labeled with 800 t~Ci [35S]methionine (>1,000 Ci/mmol) 
in 4  ml of methionine-free MEM at 370C for 30 min. The cultures were 
then washed twice and incubated in 10 ml of methionine-containing MEM 
at 37°C for various lengths of time. 
Serum Stimulation of Quiescent Cells 
Replicating  sparse  cultures  and  quiescent  confluent  cultures  grown  in 
serum-supplemented  MEM as described above were rinsed with serum-free 
MEM three times and once, respectively, refed with 10 ml of MEM contain- 
ing 0.1% serum, and allowed to incubate for 48 h to attain a uniform quies- 
cent state. The resulting quiescent cultures were incubated in 10 ml of MEM 
containing  10%  FBS  and  1%  nonessential amino acids  for  designated 
lengths of time. These cultures were then labeled at 37"C for 2 h in 4  ml 
of methionine-free  MEM  containing 500  #Ci  [35S]methionine  (>1,000 
Ci/mmol) and 10% dialyzed FBS. A serum-depleted, quiescent sparse cul- 
ture was also prepared and labeled with [35S]methionine for 2 h in the ab- 
sence of FBS. 
Cell Fractionation by Detergent Solubilization 
All steps were done at 0-40C unless otherwise indicated. [35S]Methionine- 
labeled cultures were washed four times with PBS. Cells were lysed with 
1 ml of RIPA buffer (10 mM Tris-HCl, pH 7.4,  150 mM NaCI,  1% Triton 
X-100, 0.1%  SDS,  1 mM EDTA) containing 0.5 mM PMSE  10/~g/ml of 
aprotinin, 2  /~g/ml  each of leupetin and pepstatin (all protease inhibitors 
from Boehringer Mannheim Biochemieals, Indianapolis, IN), scraped into 
Eppendorftubes, vortexed, and incubated in ice for 10 min. After a  10-min 
centrifugation at 15,000 g and 4°C, the detergent-soluble (supernatant) and 
-insoluble (pellet) fractions were separated. The soluble fraction was further 
centrifuged at  15,000  g  for  I  h  to  remove any  insoluble materials.  The 
detergent-insoluble pellet was washed once with 10 mM Tris-HCI, pH 7.4, 
and digested with 0.1 mg/ml of DNase I (Sigma Chemical Co., St.  Louis, 
MO) in 10 mM Tris-HCI, pH 7.4,  150 mM NaCI, 5 mM MgCI2, 0.5 mM 
1. Abbreviation used in this paper: CPDL, cumulative population doubling 
level; RIPA, radioimmunoprecipitation analysis. 
PMSE and 10 #g/ml of aprotinin at 4°C for 1 h with constant mixing. After 
a  10-min centrifugation, the supernatant was removed, and the pellet was 
washed once with 10 mM Tris-HCI, pH 7.4, containing 150 mM NaCI, and 
once with 10 mM Tris-HCl, pH 7.4. The pellet was then sonicated briefly 
in 300-400 #1 of 10 mM Tris-HCl, pH 7.4, 100 mM NaCI, 0.4% SDS (ref- 
erence 15) containing 0.5 mM PMSE  10 ~tg/ml of aprotinin, 2 ~tg/ml each 
of leupetin and pepstatin, and boiled for 5 min. The sample was cooled to 
room temperature and  10 mM Tris-HCl, pH 7.4, containing 20% Triton 
X-100 was added to a final concentration of 1% Triton X-100. The sample 
was then centrifuged at  15,000 g and 4°C for 30 rain to remove insoluble 
materials. The resulting supernatant represents the detergent-insoluble frac- 
tion of the cellular extract. 
lmmunoprecipitations and Gel Electrophoresis 
All steps were done at 4°C unless otherwise indicated.  Immunoprecipita- 
tions were carried out overnight in a final volume ofO.5 ml of RIPA buffer 
containing I  ×  106 acid-precipitable cpm of [3SS]methionine-labeled cellu- 
lar fractions, 3/~l of $44-1  ascite fluid, 0.5 mM PMSE  10 #g/ml of aproti- 
nin, 2/zg/ml each of leupetin and pepstatin with constant mixing. The mix- 
tures were incubated first with 20 #g of affinity-purified rabbit anti-mouse 
IgG (Cappel Laboratories, Malvern, PA) for 2 h, and then 50/~1 of a  10% 
suspension of protein A-Sepharose CL-4B (Pharmacia Fine Chemicals, 
Piscataway,  NJ) for 1 h with constant mixing. The beads were pelleted in 
a microcentrifuge and washed three times with RIPA buffer and once with 
10 mM Tris-HCI, pH 7.4.  The beads and bound proteins were boiled in 
30 #l of twice-concentrated SDS sample buffer, and the eluted proteins were 
analyzed by SDS-PAGE (11) in 10% polyacrylamide gels, followed by auto- 
radiography. For the studies on serum stimulation of quiescent cells, the au- 
toradiograms were scanned by laser densitometer (ultroscan XL; LKB In- 
struments Inc.,  Gaithersburg, MD)  for quantitative measurements of the 
relative amounts of statin. For analysis of the immunoprecipitates by two- 
dimensional PAGE (14),  the bound proteins were eluted from the beads by 
a  15-min incubation in 9.5 M urea, 2% (vol/vol) NP-40, 2% (vol/vol) Am- 
pholines (1.6%  pH  range 5-7;  0.4%  pH  range 3-10),  and 5%  (vol/vol) 
2-mercaptoethanol at room temperature. The eluted proteins were separated 
by [EF (1.6% pH range 5-7, 0.4% pH range 3-10) in the first dimension and 
SDS-PAGE in the second dimension. 
[Methyl-JH]Thymidine Incorporation 
Parallel sets of sparse cultures and confluent cultures that were made quies- 
cent by serum depletion as already described were refed with MEM sup- 
plemented with 10% FBS and i% essential amino acids and allowed to incu- 
bate  for designated lengths of time.  [Methyl-3H]thymidine (6 Ci/mmol; 
New England Nuclear) was added to a fnal concentration of 10 #Ci/ml at 
0, 3, 7,  14, 22, or 26 h after serum stimulation, the cells were incubated 
for an additional 1 h. DNA synthesis was measured by determining the in- 
corporation  of [methyl-3H]thymidine into  acid-precipitable  materials as 
described (9) with minor modifications. Cells were rinsed three times with 
PBS,  fixed in  10%  TCA for  10 min, and washed again with PBS.  The 
manipulations were carried out at 0°C. The cells were solubilized in 4 ml 
of 0.2 N  NaOH at 70"C for 10 min, and then neutralized with 0.4 ml of 
2 N HCI. To measure the radioactivity, 0.5 ml of the neutralized sample was 
taken out for scintillation counting. 
Results 
To determine whether statin was present in cellular compart- 
ments  other than the nuclear envelope, replicating sparse 
culture  and  quiescent  confluent culture  of young  human 
fibroblasts (CPDL  =  10) labeled with [35S]methionine  for 
16  h  were  lysed with  RIPA  buffer containing  1%  Triton 
X-100,  and  the  resulting detergent-soluble and  -insoluble 
fractions of the cell extracts were immunoprecipitated with 
the mAb specific for statin. Since previous studies have indi- 
cated that statin is absent in the nuclei of cells that are in the 
replicative state (20, 24), the metabolic labeling of the quies- 
cent confluent culture was done in the presence of 0.5 % in- 
stead of 10%  FBS to avoid any mitogenic effect caused by 
serum stimulation during the steady-state labeling. The repli- 
cating sparse culture was labeled in the presence of 10% FBS. 
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young human fibroblasts.  Replicating  sparse culture (a) and quies- 
cent confluent culture (b) of  young fibroblasts (CPDL =  10) labeled 
with  [35S]methionine for 16 h in the presence of 10 and 0.5%  se- 
rum, respectively,  were extracted  with RIPA buffer and separated 
into the Triton X-100-insoluble  (lane 1 ) and -soluble  (lane 2) frac- 
tions.  The cell fractions were immunoprecipitated  by the antistatin 
antibody and the resulting  immunoprecipitates  were analyzed by 
SDS-PAGE. Statin is indicated by an arrow. The positions of molec- 
ular mass markers are shown by numbers (given in kD). The band 
at 43-kD represents  actin nonspecifically  precipitated. 
Statin was present in large amounts in the Triton X-100-in- 
soluble fraction of the quiescent confluent culture (Fig.  1 b, 
lane/), but not in that of the replicating sparse culture (Fig. 
1 a,  lane/).  These results are consistent with the previous 
studies  that  determined  statin  was  present  in  the  nuclear 
envelope of density-arrested young fibroblasts and absent in 
the  nuclear  envelope  of replicating  young fibroblasts  (20, 
22).  DNase  treatment  of the  Triton  X-100-insoluble  frac- 
tions did not release statin (data not shown). Actin, a 43-kD 
major protein  in the Triton  X-100-insoluble  fraction,  was 
coprecipitated  by  the  antistatin  antibody  (Fig.  1,  a  and b, 
lanes/).  The nonspecific immunoprecipitation of actin has 
also been  seen  with other antibodies  (12).  Statin  was also 
found in the Triton X-100-soluble fractions of both the repli- 
cating sparse culture and quiescent confluent culture (Fig.  1, 
a  and b, lanes 2).  Since integral membrane proteins of nu- 
clear envelope are Triton X-100 insoluble,  the presence of 
statin in the Triton X-100-soluble fractions of these cultures 
indicates that a population of the protein is located in other 
cellular compartment(s) besides the nuclear envelope. These 
results,  taken together, demonstrate that two populations of 
statin  exist:  the  Triton  X-100-insoluble  population  that  is 
an integral protein of the nuclear envelope,  and the Triton 
X-100-soluble population that is located in the other cellular 
compartment(s).  The Triton X-100-insoluble statin is pres- 
Figure 2. Two-dimensional  gel analysis of statin. The Triton X-100- 
insoluble  (A) and -soluble  (B)  fractions  from the quiescent con- 
fluent  culture  of young fibroblasts  (CPDL  =  10)  labeled  with 
[35S]methionine for  16 h  were immunoprecipitated  with the  an- 
tistatin antibody. The immunoprecipitates  were subjected to IEF in 
the first dimension (acidic end starts from the left) and SDS-PAGE 
in the second dimension (positions  of molecular mass markers are 
shown by numbers).  Statin (S) and nonspecifically  precipitated  ac- 
tin (A) are indicated  by arrows.  In a, the three spots at the upper 
left corner and  two  spots  at the  lower  right corner are position 
marks put on the dried SDS-polyacrylamide gel to make alignment 
of the gel with  the autoradiogram easier. 
ent specifically in the quiescent confluent culture,  whereas 
the Triton X-100-soluble statin is present in the replicating 
sparse culture as well as in the quiescent confluent culture 
of young human fibroblasts. 
The Triton  X-100-insoluble  and  -soluble  fractions  from 
the quiescent confluent culture of young human fibroblasts 
(CPDL  =  10) labeled  with  [3~S]methionine for  16 h  were 
immunoprecipitated  with  the  antistatin  antibody  and  ana- 
lyzed by two-dimensional gel electrophoresis.  Fig. 2  shows 
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cent confluent cultures  of young fibroblasts (CPDL  =  10) were 
pulse labeled with [35S]methionine for 30 min (lanes 1 and 4) and 
chased in serum-free medium containing unlabeled  L-methionine 
for 30 (lanes 2 and 5) or 90 min (lanes 3 and 6). The Triton X-100- 
insoluble (lanes 1-3) and -soluble (lanes 4-6) fractions obtained 
from these cells by RIPA buffer extraction were immunoprecipi- 
tated with the  antistatin  antibody. The immunoprecipitates  were 
subjected to SDS-PAGE. Statin is indicated by an arrow (left). The 
band at 43 kD in lanes 1-3 represents actin nonspecifically precipi- 
tated. 
that statin in both fractions exhibited an isoelectric point of 
5.3 and appeared to exist as single isoform since longer ex- 
posure of the autoradiograms did not reveal more than one 
57-kD species. 
To investigate whether statin was synthesized as a  57-kD 
protein or was processed from a precursor of different mo- 
lecular mass, quiescent  confluent cultures  of young fibro- 
blasts (CPDL  =  10)  were pulse labeled with  [35S]methio- 
nine  in  the  absence  of serum  for 30  min  and  chased  for 
various lengths of time in a serum-free medium containing 
unlabeled methionine. After the pulse labeling or designated 
periods of chases,  cells  were lysed  with  RIPA buffer and 
separated into Triton X-100-insoluble and -soluble fractions 
which were then immunoprecipitated with the antistatin anti- 
body. As it is the case for the steady-state labeled quiescent 
cells (Fig.  1 b, lanes 1 and 2),  statin in the cells pulsed la- 
beled for 30 min was synthesized as a 57-kD protein which 
was detected in both the Triton X-100-insoluble and -soluble 
fractions (Fig. 3, lanes 1 and 4). The same 57-kD protein was 
detected in the two fractions after 30 and 90 min of chases 
(Fig.  3,  lanes  2  and  5,  and  lanes  3  and  6,  respectively). 
Longer chases for up to 14 h also did not reveal any species 
other than the 57-kD protein (data not shown). 
Previous studies  have demonstrated that the  nuclear ex- 
pression of statin is correlated to the nonprotiferative state 
of the cell (20,  22,  24).  Since statin is found to be present 
in the Triton X-100-insoluble and -soluble fractions of the 
cell extracts (Fig.  1), it is important to further investigate the 
correlation between the synthesis of total cellular statin and 
the proliferation state of the cell.  To perform such a study, 
replicating sparse cultures and quiescent confluent cultures 
of young  fibroblasts  (CPDL  =  13)  were made uniformly 
quiescent  by serum depletion,  and the  resulting quiescent 
cultures were stimulated with 10% serum for various lengths 
of time and then labeled with pS]methionine for 2 h in the 
presence of 10%  serum. Synthesis of statin was determined 
by immunoprecipitation of the Triton X-100-insoluble and 
-soluble fractions from the labeled cultures extracted with 
RIPA buffer, followed by quantitative measurements of the 
relative amounts of statin by densitometric analysis of the au- 
toradiograms obtained from gel electrophoresis of the  im- 
munoprecipitates.  To correlate synthesis of statin with the 
proliferation state of the cells, cellular DNA synthesis after 
serum stimulation  was measured by [methyl-3H]thymidine 
incorporation into parallel cultures. 
Fig. 4 shows that 5 h after the addition of serum to quies- 
cent confluent culture,  synthesis of total cellular statin de- 
creased (compare lanes 1 and 5  with lanes 2  and 6),  with 
newly synthesized statin present at a  slightly reduced level 
(80%) in the soluble fraction (lane 6) and at a substantially 
reduced  level  (48%)  in  the  insoluble  fraction (lane 2).  In 
contrast,  synthesis of the  coprecipitated actin began to in- 
crease (Fig. 4, compare lanes 1 and 2).  By 9 h after serum 
stimulation, synthesis of the Triton X-100-soluble statin was 
drastically reduced (to  15%) (Fig. 4,  compare lanes 6 and 
7), whereas synthesis of the Triton X-100-insoluble statin re- 
mained at approximately the same low rate as that of the 5-h 
serum stimulation (Fig. 4, compare lanes 2 and 3).  A  16-h 
serum stimulation did not cause any further change in syn- 
thesis of both populations of statin (Fig. 4,  lanes 4 and 8). 
Synthesis of both populations of statin thus appeared to drop 
to a  low,  constant level which probably represents a  basal 
level of the protein in the serum-stimulated confluent culture. 
It should be noted that the rapid decrease in synthesis of total 
cellular statin occurred before a substantial increase in DNA 
synthesis  was detected  at  14-15  h  after addition  of serum 
(Table I). 
Fig. 5 a shows that in quiescent sparse culture labeled with 
pS]methionine for 2 h in the absence of serum, statin was 
present in both the Triton X-100-insoluble and -soluble frac- 
tions. When the culture was labeled for 2 h in the presence 
of 10% serum, synthesis of the Triton X-100-insoluble statin 
was turned off rapidly by a 2-h serum stimulation during the 
labeling, whereas synthesis of the Triton X-100-soluble sta- 
tin did not change (compare lanes 1 and 2 of Fig.  5 a  with 
lanes I and 5 of Fig. 5 b). However, after 5 h of serum stimu- 
lation,  a  decrease  (to  83%)  in  the  synthesis of the  Triton 
X-100-soluble statin began to be detected (Fig. 5 b, compare 
lanes 5 and 6). It is noteworthy that this decrease occurred 
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detected (see Table I). A 9-h serum stimulation caused fur- 
ther decrease (to 67 %) in synthesis of the Triton X-100-solu- 
ble statin (Fig. 5 b, lane 7). By the time DNA synthesis in- 
creased substantially after 16 h of serum stimulation (Table 
I), synthesis of the Triton X-100-soluble statin had dropped 
to a very low level (22%) (Fig. 5 b, lane 8), which probably 
represents a basal level of the protein in the sparse culture 
serum-stimulated to reenter the S phase of the cell cycle. In 
comparison to the confluent culture (Fig. 4, lanes 6-8), syn- 
thesis of the Triton X-100-soluble statin in the sparse culture 
decreased in a more gradual manner and to a lesser extent 
after 16 h of serum stimulation (Fig. 5 b, lanes 6-8). On the 
other hand, synthesis of the coprecipitated actin in the sparse 
culture increased during serum stimulation (Fig. 5 b, lanes 
1-4), as is the case for the confluent culture (Fig. 4, lanes 
1-4). 
Figure 4. Synthesis of statin in serum-stimulated confluent cultures. 
Quiescent confluent cultures of young fibroblasts (CPDL  =  13) 
were stimulated with 10% serum for 0 (lanes 1 and 5), 3 (lanes 2 
and 6), 7 (lanes 3 and 7), or 14 h (lanes 4 and 8), and then labeled 
with [3SS]methionine  for 2 h in the presence of 10% serum. The 
Triton X-100-insoluble (lanes 1-4) and -soluble (lanes 5-8) frac- 
tions obtained from these cells by RIPA buffer extraction were im- 
munoprecipitated by the antistatin antibody. The immunoprecipi- 
tates were analyzed by SDS-PAGE. Statin is indicated by an arrow. 
The band at 43 kD in lanes 1-4 represents actin nonspecifically 
precipitated. 
Table L DNA Synthesis in Serum-stimulated Cultures 
of Young Fibroblasts 
[methyl-3H]Thymidine incorporation 
Hours of 
serum stimulation  Quiescent confluent cultures  Quiescent sparse cultures 
before labeling  (6 ×  10  s  cells/cm  2)  (9 ×  10  3  cells/cm  2) 
cpm  cpm 
0  10,780  12,778 
3  15,242  18,031 
7  19,774  24,878 
14  37,312  46,341 
22  60,210  84,366 
26  77,801  104,861 
Quiescent sparse and confluent cultures were serum stimulated for designated 
lengths of time and then labeled with [methyl-3H]thymidine for 1 h. The la- 
beled cells  were washed,  fixed with TCA, and solubilized in 4 ml of 0.2  N 
NaOH,  followed by neutralization  with 0.4 ml of 2 N HCI. To measure the 
incorporation of radioactive label, 0.5 ml of the neutralized sample was taken 
out for scintillation counting. The measurement obtained from this scintillation 
counting was used for calculation of total [methyl-~H]thymidine incorporation 
into the culture. 
Discussion 
In this report we demonstrate by immunoprecipitation analy- 
sis  of fractionated cell extracts prepared from replicating 
sparse cultures, quiescent confluent cultures, and quiescent 
serum-starved cultures of young human fibroblasts that there 
exist two populations of statin: one that is Triton X-100 solu- 
ble and  is  present  in  replicating fibroblasts as  well as  in 
quiescent ones, and the other that is Triton X-100 insoluble 
and is present only in quiescent cells. That the Triton X-100- 
insoluble statin is found only in the quiescent cells is consis- 
tent with the previous immunogold labeling data (22) that 
statin is present in the nuclear envelope of quiescent fibro- 
blasts but absent in that of replicating fibroblasts. Taken to- 
gether, these results suggest that the Triton X-100-soluble 
statin, unlike the Triton X-100-insoluble one, is located in 
cellular compartment(s) other than the nuclear envelope. 
Pulse-chase  analysis  of quiescent  confluent cultures  of 
young human fibroblasts shows that statin is synthesized as 
a 57-kD polypeptide and is not processed from a precursor 
of different molecular mass.  In cells pulse labeled for 30 
min, the newly synthesized protein was found in both the Tri- 
ton X-100-insoluble and -soluble fractions, following a dis- 
tribution similar to the steady-state one. No precursor-prod- 
uct  relationship  between  the  Triton  X-100-soluble  and 
-insoluble statins was detected during the pulse and chase 
periods.  However,  analysis  by  two-dimensional  gel  elec- 
trophoresis shows that both populations of statin exhibit an 
isoelectric point of 5.3 and that only a single isoform is de- 
tected by the antistatin mAb. This suggests that there may be 
only one biochemically distinct species of statin and that the 
Triton X-100--soluble  statin could be converted into the in- 
soluble one by being assembled into the nuclear envelope or 
associated with other protein complexes there. It is possible 
that the conversion of the Triton X-100-soluble statin into the 
Triton X-100-insoluble one is a rapid process and takes less 
than 30 min, and that a constant level of the Triton X-100- 
soluble statin is maintained in the cells. If this is the case, 
the precursor-product relationship between the two popula- 
tions of statin could not be readily detected during the chase 
periods of 30 min or longer, and the newly synthesized Triton 
X-100-insoluble statin detected in the 30-min pulse period 
could be originated from the Triton X-100-soluble one. More 
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stimulated  sparse  cultures.  (a)  Quies- 
cent sparse culture of young fibroblasts 
(CPDL =  13) labeled with [35S]methio- 
nine for 2 h in the absence of serum was 
extracted  with  RIPA buffer and  sepa- 
rated  into  the  Triton  X-100-insoluble 
(lane I) and -soluble (lane 2) fractions. 
(b) Quiescent sparse cultures  of young 
fibroblasts (CPDL  =  13)  were  stimu- 
lated with 10% serum for 0 (lanes 1 and 
5), 3 (lanes 2 and 6), 7 (lanes 3 and 7), 
or 14 h (lanes 4 and 8) and then labeled 
with  [3SS]methionine for  2  h  in  the 
presence  of  10%  serum.  The  labeled 
cultures were extracted with RIPA buffer 
and separated into the Triton X-100-in- 
soluble (lanes 1-4) and -soluble (lanes 
5-8) fractions.  All cell fractions  were 
immunoprecipitated by the antistatin an- 
tibody and the resulting immunoprecipi- 
tates were subjected to SDS-PAGE. Sta- 
tin is indicated by an arrow. The band at 
43-kD  represents  actin  nonspecifically 
precipitated. 
elaborate experiments will be needed  to verify this possi- 
bility. 
Our present studies also demonstrate that synthesis of both 
the Triton X-100-insoluble and -soluble statin decreases sub- 
stantially  when serum-depleted quiescent cells are serum- 
stimulated to leave the GO phase of the cell cycle, and this 
decrease precedes reinitiation of DNA synthesis. These re- 
suits suggest that statin is synthesized preferentially and is 
present in greater abundance during the GO phase of the cell 
cycle. In particular, the fact that a large amount of the Triton 
X-100-insoluble statin is present specifically in the nuclear 
envelope  of  quiescent  fibroblasts  confirms  the  previous 
findings  (22,  25)  that the  nuclear  statin can  be used as a 
marker for cells arrested at the GO phase. Thus, cellular ex- 
pression of statin appears to be associated with the mecha- 
nisms controlling the transition between the growing state 
and the quiescent state. 
It should be noted that synthesis of the Triton X-100-in- 
soluble statin is reduced more rapidly by serum stimulation 
than synthesis of the Triton X-100-soluble statin.  In quies- 
cent confluent culture, synthesis of the Triton X-100-insolu- 
ble statin dropped drastically to a low basal level after a 5-h 
serum stimulation. In quiescent sparse culture, synthesis of 
the Triton X-100-insoluble statin was more responsive to se- 
rum and was turned off during the 2-h labeling in the pres- 
ence of 10%  serum. In both kinds of cultures, a substantial 
increase in DNA synthesis was not detected until ,o14-15 h 
after serum stimulation.  There thus exists a lag of 10-13 h 
between  reinitiation  of DNA  synthesis  and  the  observed 
changes in synthesis of the Triton X-100-insoluble statin in- 
duced in the sparse cultures and confluent cultures by serum 
stimulation.  Previous  immunofluorescence  studies  have 
shown that statin disappears rapidly from the nuclei  when 
serum-depleted  cells are  promoted  to  leave the  quiescent 
state upon serum stimulation and that this loss of nuclear sta- 
tin occurs before DNA synthesis (25).  Together with these 
previous data, the 10-13-h lag suggests that an early inhibi- 
tion in synthesis of the Triton X-100-insoluble statin induced 
by serum stimulation may be important to ensure a rapid dis- 
appearance of the protein from the nuclear envelope of the 
serum-stimulated cells, a step which may be necessary be- 
fore DNA synthesis can be reinitiated.  Since it is possible 
that there may be only one biochemically distinct species of 
statin and the Triton X-100-soluble statin could be converted 
into the insoluble form by being assembled into the nuclear 
envelope (see Discussion above), the observed reduction in 
the amounts of the newly synthesized Triton X-100-insoluble 
statin in the serum-stimulated cells may reflect an inhibition 
in the rate of assembly of the protein into the nuclear enve- 
lope rather than synthesis of the protein per se. This inhibi- 
tion of the assembly rate, accompanied by a decrease in the 
synthesis of the Triton X-100-soluble statin,  could account 
for the rapid disappearance of the protein from the nuclear 
envelope of the serum-stimulated cells before reinitiation of 
DNA synthesis. Presently, it is not known whether the nu- 
clear envelope-localized, Triton X-100-insoluble statin plays 
any role in maintaining cells in the quiescent state and/or in- 
activating DNA synthesis, thereby preventing cells from en- 
try into the S phase of the cell cycle. 
It is interesting to make a comparison between statin and 
another nuclear protein, cyclin. Cyclin, also called prolifer- 
ating cell nuclear antigen (12,  13,  18),  is a nuclear protein 
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cells and preferentially synthesized during the S phase of the 
cell cycle (1, 2, 5, 8,  10). Immunofluorescence studies have 
revealed dramatic changes in its nuclear distribution during 
the S phase (3, 7). It has recently been shown to be an aux- 
iliary protein for DNA polymerase-t5  (6,  17,  19),  and re- 
quired for SV40 DNA replication in vitro (16). At the time 
this manuscript was prepared, Bravo and Macdonald-Bravo 
(4) reported existence of two populations of cyclin during the 
S phase: one that is nucleoplasmic and is extracted by Triton 
X-100, and another that is associated with the DNA replica- 
tion sites and is Triton X-100-insoluble. The nucleoplasmic, 
detergent-soluble cyclin, but not the detergent-insoluble one, 
is also found in quiescent cells. Although statin and cyclin 
show different expression patterns and seem to play different 
roles in the control of cell proliferation, both of them exist 
in two populations in the cells. Presently, it is not clear what 
the significance of having two populations of these proteins 
is, and whether existence of two populations of a protein is 
a common phenomenon for proteins involved in the mecha- 
nisms controlling cell proliferation. It is also not known if 
there is any interaction between the proteins. Further studies 
with these and other proteins associated with cell growth are 
needed to answer the questions. 
We thank Mr. Steve Young for technical  assistance in two-dimensional gel 
electrophoresis and Dr. Lester May for help with densitometric scanning 
of autoradiograms. 
This work was supported by research grant AG03020 to E. Wong and 
postdoctoral fellowship AG05385  to G. Ching from the National  Institute 
on Aging. 
Received  for publication 31  May  1989 and in revised form 7 September 
1989. 
References 
I. Bravo, R. 1986. Synthesis of  the nuclear protein cyclin (PCNA) and its rela- 
tionship with DNA replication.  Exp. Cell Res.  163:287-293. 
2. Bravo, R., andJ. E. Cells.  1980. A search for differential polypeptide syn- 
thesis throughout the cell cycle of HeLa cells. J.  Cell  Biol. 84:795-802. 
3. Bravo, R., and H. Macdonald-Bravo.  1985. Changes in the nuclear distri- 
bution of  cyclin (PCNA) but not its synthesis depend on DNA replication. 
EMBO (Eur. Mol. Biol.  Organ.) J.  4:655-661. 
4. Bravo, R., and H. Macdonald-Bravo.  1987. Existence of two populations 
of cyclin/proliferating cell nuclear antigen during the cell cycle: associa- 
tion with DNA replication sites. J.  Cell Biol. 105:1549-1554. 
5. Bravo, R., S. J. Fey, J. Bellatin, P.  Mose Larsen, J. Arevalo,  and J. E. 
Celis.  1981. Identification of a nuclear and of a cytoplasmic polypeptide 
whose relative proportions  are  sensitive to changes in the rate of cell 
proliferation.  Exp. Cell Res. 136:311-319. 
6. Bravo, R., R. Frank, P. A. Blundell, and H. Macdonald-Bravo.  1987. Cy- 
clin/PCNA  is  the  auxiliary  protein  of  DNA  polymerase-5.  Nature 
(Lond.). 326:515-517. 
7. Celis, J. E., and A. Celis.  1985. Cell cycle-dependent variations in the dis- 
tribution of the nuclear protein cyclin in cultured cells. Proc. Natl. Acad. 
Sci.  USA. 82:3262-3266. 
8. Celis, J. E., P. Madsen, S. Nielsen, and A. Celis.  1986. Nuclear patterns 
of  cyclin (PCNA) antigen distribution subdivide S-phase in cultured cells. 
Leuk.  Res. 10:237-249. 
9.  Holleoberg,  M.  D.,  and  P.  Cuatrecasas.  1975. Insulin  and  epidermal 
growth  factor:  human fibroblast receptors  related to deoxyribonucleic 
acid synthesis and amino acid uptake. J.  Biol. Chem. 250:3845-3853. 
10. Kurki, P., M. Vanderlaan,  F.  Dolheare, J. Gray,  and ~E. M. Tan.  1986. 
Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the 
cell cycle. Exp. Cell Res.  166:209-219. 
11.  Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly 
of the head of bacteriophage T4. Nature  (Lond.). 227:680-685. 
12.  Mathews, M. B., R. M. Bernstein, B. R. Franza, and J. 1. Garrels.  1984. 
The identity of the proliferating cell nuclear antigen and cyclin. Nature 
(Lond.).  309:374-376. 
13. Miyashi, K., M. J. Fritzler,  and E. M. Tan.  1978. An autoantibody to a 
nuclear antigen in proliferating  cells. J.  lmmunol.  121:2228-2234. 
14. O'Farrell,  P. H. 1977. High resolution two-dimensional electrophoresis of 
proteins. J.  BioL Chem. 250:4007-4021. 
15. Ottaviano, Y., and L. Gerace.  1985. Phosphorylation of the nuclear lamins 
during  interphase and mitosis. J.  Biol. Chem. 260:624-632. 
16. Prelich, G., M. Kostura, D. R. Marshak, M. B. Mathews, and B. Stillman. 
1987. The cell-cycle regulated proliferating  cell nuclear antigen is re- 
quired for SV40 DNA replication in vitro. Nature (Lond.). 326:471-475. 
17.  Prelich,  G., C. K. Tan,  M. Kostura,  M. B. Mathews, A. G. So, K. M. 
Downey, and B. Stillman.  1987. Functional identity of proliferating cell 
nuclear  antigen  and  a  DNA  polymerase-~5 auxiliary  protein.  Nature 
(Lond.). 326:517-520. 
18. Takasaki,  J.,  D.  Fischwild,  and  E.  M.  Tan.  1984. Characterization  of 
proliferating cell nuclear antigen recognized by autoantibodies in lupus 
sera. J.  EXp. Med. 159:981-992. 
19. Tan, C. K., C. Castillo, A. G. So, and K. M. Downey.  1986. An auxiliary 
protein  for DNA polymerase-t5 from fetal calf thymus. J.  BioL Chem. 
261:12310-12316. 
20. Wang, E. 1985. A 57,000-mol-wt protein uniquely present in nonproliferat- 
ing cells and senescent human fibroblasts. Jr.  Cell BioL 100:545-551. 
21. Wang, E.  1985. Are cross-bridging structures involved in the bundle for- 
mation of intermediate filaments and the decrease in locomotion that ac- 
company cell aging? J.  Cell BioL 100:1466-1473. 
22. Wang,  E.  1985.  Rapid disappearance  of statin,  a  nonproliferating  and 
senescent cell-specific protein,  upon reentering the process of cell cy- 
cling. J.  Cell Biol. 101:1695-1701. 
23. Wang, E., and D. Gundersen.  1984. Increased organization ofcytoskeleton 
accompanying the aging of human fibroblasts in vitro. EXp. Cell Res. 
t54:191-202. 
24. Wang,  E., and J. G. Krueger.  1985. Application of a unique monoclonal 
antibody as a marker for nonproliferating subpopulations of cells of some 
tissues. J.  Histochem.  Cytochem. 33:587-595. 
25. Wang, E., and S. L. Lin.  1986. Disappearance of statin, a protein marker 
for nonproliferating and senescent cells, following serum stimulated cell 
cycle entry.  EXp. Cell Res.  167:135-143. 
Ching and Wang Characterization of Two Populations of Statin  261 